Drugs / Tavilermide
Tavilermide
also known as
MIM-D3 · D-3 hydrochloride · MIM D-3 HYDROCHLORIDE · MPS-429 · Tavilermida · TAVILERMIDE HYDROCHLORIDE
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01257607 | Nov 2010 → May 2011 | dry eye syndrome | Mimetogen Pharmaceuticals USA, Inc. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05848128 | Jun 2023 → May 2024 | dry eye syndrome | Mimetogen Pharmaceuticals USA, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03925727 | Mar 2019 → Jun 2020 | dry eye syndrome | Mimetogen Pharmaceuticals USA, Inc. | Completed | Mixed |
| Comparator or background therapy3 trials | ||||||
| Phase 3 | NCT02665234 Comparator | Jan 2016 → Feb 2017 | dry eye syndrome | Mimetogen Pharmaceuticals USA, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02634853 Comparator | Dec 2015 → Feb 2017 | dry eye syndrome | Mimetogen Pharmaceuticals USA, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01960010 Comparator | Oct 2013 → Aug 2014 | dry eye syndrome | Mimetogen Pharmaceuticals USA, Inc. | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-03-31 | Mimetogen Pharmaceuticals USA, Inc. | Mimetogen pharmaceuticals completes enrollment of mim-728 phase 3 trial for tavilermide for dry eye disease mimetogen.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tavilermide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02634853 ↗ |
| Known as | D-3 hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544981 ↗ |
| Known as | MIM D-3 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544981 ↗ |
| Known as | MIM-D3 | “A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease” NCT02665234 ↗3“A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye” NCT02634853 ↗ |
| Known as | MPS-429 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544981 ↗ |
| Known as | Tavilermida | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544981 ↗ |
| Known as | TAVILERMIDE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544981 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL3544981 ↗ |
| Route | Other | “MIM-D3 Ophthalmic Solution” NCT01257607 ↗ |